A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors-Reference-Cited by-同舟云学术

A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

Published:2021-04-14 Issue:5 Volume:39 Page:1284-1297
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Falchook Gerald S.,Peeters Marc,Rottey Sylvie,Dirix Luc Y.,Obermannova Radka,Cohen Jonathan E.,Perets Ruth,Frommer Ronnie Shapira,Bauer Todd M.,Wang Judy S.,Carvajal Richard D.,Sabari Joshua,Chapman Sonya,Zhang Wei,Calderon Boris,Peterson Daniel A.

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-021-01088-4.pdf

Reference32 articles.

1. Yin Z, Bai L, Li W, Zeng T, Tian H, Cui J (2019) Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy. J Exp Clin Cancer Res 38(1):403. https://doi.org/10.1186/s13046-019-1409-3

2. Thommen DS, Schumacher TN (2018) T cell dysfunction in Cancer. Cancer Cell 33(4):547–562. https://doi.org/10.1016/j.ccell.2018.03.012

3. Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39(1):98–106. https://doi.org/10.1097/COC.0000000000000239

4. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Marquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schoffski P, Carlino MS, Lebbe C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD (2019) Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 381(16):1535–1546. https://doi.org/10.1056/NEJMoa1910836

5. Gonzalez-Martin A, Sanchez-Lorenzo L (2019) Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: still promising? Cancer 125(Suppl 24):4616–4622. https://doi.org/10.1002/cncr.32520

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of tumor-associated macrophages in hepatocellular carcinoma: impact, mechanism, and therapy;Frontiers in Immunology;2024-08-07

2. Therapeutic treatments targeting communication between angiogenic and immune microenvironments in thyroid cancers;Current Opinion in Endocrine and Metabolic Research;2024-08

3. Tumor‐associated macrophages: A sentinel of innate immune system in tumor microenvironment gone haywire;Cell Biology International;2024-07-25

4. Paracrine Ovarian Cancer Cell‐Derived CSF1 Signaling Regulates Macrophage Migration Dynamics in a 3D Microfluidic Model that Recapitulates In Vivo Infiltration Patterns in Patient‐Derived Xenografts;Advanced Healthcare Materials;2024-06-05

5. Macrophage‐Capturing Self‐Assembly Photosensitizer Nanoparticles Induces Immune Microenvironment Re‐Programming and Golgi‐Responsive Immunogenic Cell Death in Head and Neck Carcinoma;Advanced Healthcare Materials;2024-04-09